|
|
Blood, Vol. 109, Issue 8, 3177-3188, April 15, 2007
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Blood Mulligan et al.
109: 3177
Supplemental materials for: Mulligan et al, Vol 109, Issue 8, 3177-3188
Files in this Data Supplement:
- Table S1. Quality control metrics used as inclusion criteria for sample analysis (PDF, 9.84 KB)
- Table S2. Numbers of patients providing pharmacogenomics data in the 024, 025, 039, and 040 studies who were evaluable for response, time to progression, and overall survival (PDF, 9.90 KB)
- Table S3. Comparison of criteria and data for trials in which genomic research was conducted (PDF, 10.5 KB)
- Table S4. Linear predictor probe sets to distinguish patients with a response and patients with progressive disease (PDF, 96.7 KB)
- Table S5. Progressive disease versus response and nonresponse/response prediction results using trial 039 Dex and trial 039 bortezomib as independent data (PDF, 9.94 KB)
- Table S6. The 100 probe sets derived from 025 + 040 trials and used in Super PC prediction of survival classifier (PDF, 30.8 KB)
- Figure S1. Response prediction (PDF, 54.0 KB) -
(A) Key characteristics of PD versus R and NR versus R classifiers when evaluated in the trial 039 bortezomib patient dataset. (B) NR versus R, 1000 bootstraps with permuted sample labels.
- Figure S2. Balanced categories (PDF, 27.1 KB)
|
|
